Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s ...

most studies of ketamine in depression have relied on either intravenous or intranasal administration, the latter resulting in the approval of J&J’s Spravato (esketamine) for TRD in 2019 and for ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other psychedelic ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

The latest issues of two American Psychiatric Association journals, The American Journal of Psychiatry and Psychiatric Services, are now available online.